What a 2026 vitamin D meta-analysis found in multiple sclerosis

Vitamin D keeps turning up in multiple sclerosis research. Li et al.'s 2026 systematic review and meta-analysis narrows the question rather than settling it. Across 62 studies, people with MS had lower serum 25(OH)D levels than controls, and relapsing-remitting patients in relapse had lower levels than those in remission. The supplementation half of the paper landed softer: no significant overall benefit on annualized relapse rate or disability scores, though one high-dose vitamin D3 subgroup produced a signal that caught attention.

A narrower reading matters here. Vitamin D occupies the overlap between deficiency medicine and disease-modifying optimism — precisely where supplement narratives outpace the evidence. The question worth asking is whether Li et al. 2026 produced evidence strong enough to treat supplementation as a relapse-lowering strategy for MS. On the paper’s own terms: not broadly, not yet.

Clinicians circle back because low vitamin D status shows up repeatedly in MS cohorts, and deficiency is easier to measure and correct than most neurological risk factors. Practicality gives the topic its staying power. But the literature’s central problem hasn’t changed. Three separate claims: association, supplementation, and disease modification.

What the 2026 meta-analysis actually found

Easiest to overread: the observational findings. In the full Frontiers in Immunology article, Li and colleagues pooled 40 observational studies and 22 supplementation studies. Vitamin D status ran lower in MS overall (weighted mean difference −4.54) and lower still when relapsing-remitting patients were in relapse versus remission (WMD −7.05). Interesting signals. But an association is not proof that low vitamin D drives relapses.

Observational associations host plenty of alternative explanations. People with more active disease may spend less time outdoors. Disability shifts diet, activity, and sun exposure. Steroid use, body composition, latitude, and season all distort serum vitamin D measurements — without clarifying causality. The association still carries weight: vitamin D status tracks with disease burden in some cohorts. Tracking is not the same as determining.

Where the relapse-rate signal gets tricky

Public framing started to split at the intervention data. Li et al. 2026 found no statistically significant overall effect on annualized relapse rate (pooled WMD −0.07) and no significant effect on EDSS disability scores (WMD 0.02). The same paper also reported a significant ARR reduction in a high-dose vitamin D3 subgroup (WMD −0.21). Medical Dialogues highlighted that subgroup finding in its trade coverage.

Elsewhere, the framing landed differently. Multiple Sclerosis News Today described a separate 2026 meta-analysis that found the strongest relapse signal at low to moderate doses, not the high end. Two pooled analyses, appearing around the same time, point readers in opposite directions. The dose question is still unstable. When heterogeneity is that visible, it is the story — not a footnote.

Small trials explain a lot of the variance. Supplementation studies in MS differ on baseline deficiency, disease stage, concurrent disease-modifying treatment, vitamin D formulation, follow-up length, and the outcome each team prioritized. A subgroup finding inside that kind of literature can be useful — or a reflection of trial design rather than a clean dosing rule. Anyone tempted to turn the high-dose signal into a self-experiment should slow down.

Outcome choice adds more noise. Relapse counts can shift without a parallel movement in disability scales, especially in short follow-ups with mixed populations. That split explains why a pooled hint on ARR sits alongside a flat EDSS result. The paper reads more like a prompt for better-targeted trials than a finished clinical instruction.

What the rest of the literature says

Earlier reviews have been cautious along the same lines. In a 2019 review on vitamin D and disease activity in MS, Holmøy wrote that people with MS should avoid vitamin D insufficiency and aim for levels around 100 nmol/L or somewhat higher. Clinically practical advice. Also far more conservative than the way supplement marketing tends to translate the literature. Avoiding insufficiency is one thing; proving that escalating beyond adequacy changes relapse biology is another.

A 2021 expert opinion paper on vitamin D supplementation in MS argued a related point from another angle: any benefit may be more plausible in early disease, clinically isolated syndrome, or patients deficient at baseline than in broad, mixed MS populations. The evidence stays ambiguous. But the paper helps with reading the literature: correcting a deficiency in the right patient is a narrower, more believable clinical use case than treating vitamin D as a stand-alone disease-modifying therapy.

What readers should do with this evidence

For patients and clinicians, the defensible near-term conclusion is unglamorous. Check whether someone with MS is actually deficient. Correct it with medical guidance. Keep expectations modest when the conversation moves from general health to relapse prevention. Anyone considering supplementation should consult their doctor first — dose, monitoring, and toxicity risk matter more in chronic use than most headlines admit.

High-dose trial protocols and self-directed over-the-counter routines are not the same thing. The studies in this literature came with entry criteria, follow-up schedules, and clinical oversight. Strip away that scaffolding and “high dose” loses most of its meaning. A dose headline matters less than remembering that an adjunct signal is not a treatment substitute.

Restraint feels unsatisfying — that is the hard part for readers. Li et al. 2026 did not conclude that vitamin D has no role in MS. The paper surfaced a biologically plausible, clinically interesting, fragmented body of evidence: lower vitamin D status is common in MS, relapse activity may track with lower levels, and some supplementation subgroups show signals that deserve better trials. What the paper did not do was establish a clear overall benefit on the endpoints that matter most.

Read as a boundary-setting paper, the 2026 meta-analysis makes more sense. It keeps the vitamin D question alive — for deficiency correction, and maybe for carefully defined subgroups. It does not justify the leap from signal to strategy. For an audience accustomed to wellness certainty, that ending may feel disappointing. For science journalism, it is the honest one.

References

Li Y, Cai Y, et al. Vitamin D status, supplementation, and multiple sclerosis. Frontiers in Immunology. 2026. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1775270/full
Holmøy T. An update on vitamin D and disease activity in multiple sclerosis. Springer. 2019. https://link.springer.com/article/10.1007/s40263-019-00674-8?error=cookies_not_supported&code=0852d739-4b2f-4194-8987-87e414190527
Boltjes et al. Vitamin D supplementation in multiple sclerosis: an expert opinion. Taylor & Francis. 2021. https://www.tandfonline.com/doi/full/10.1080/14737175.2021.1935878